These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11176835)

  • 1. Influenza vaccine for healthy working adults.
    Chu SY; Singleton JA; McCauley MM; Orenstein WA; Hughes JM; Mawle AC; Modlin JF
    JAMA; 2001 Jan; 285(3):291-2. PubMed ID: 11176835
    [No Abstract]   [Full Text] [Related]  

  • 2. Influenza vaccine for healthy working adults.
    Nichol KL
    JAMA; 2001 Jan; 285(3):290; author reply 292. PubMed ID: 11176832
    [No Abstract]   [Full Text] [Related]  

  • 3. Influenza vaccine for healthy working adults.
    Muennig P
    JAMA; 2001 Jan; 285(3):291; author reply 292. PubMed ID: 11176834
    [No Abstract]   [Full Text] [Related]  

  • 4. Influenza vaccine for healthy working adults.
    Byrnes GB; Kelly H
    JAMA; 2001 Jan; 285(3):290-1; author reply 292. PubMed ID: 11176833
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaccine cost-effective, but underused.
    Nurs Manage; 2002 Oct; 33(10):10. PubMed ID: 12408137
    [No Abstract]   [Full Text] [Related]  

  • 6. Influenza vaccination cost effective in U.S. adults.
    Geriatrics; 2006 Feb; 61(2):14. PubMed ID: 16502520
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.
    Postma MJ; Jansema P; van Genugten ML; Heijnen ML; Jager JC; de Jong-van den Berg LT
    Drugs; 2002; 62(7):1013-24. PubMed ID: 11985488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of prophylaxis and treatment of influenza].
    Rychlik R; Heinen-Kammerer T; Rusche H; Piercy J; Scuffham P; Zöllner Y
    Dtsch Med Wochenschr; 2003 Oct; 128(43):2267-70. PubMed ID: 14574642
    [No Abstract]   [Full Text] [Related]  

  • 11. Influenza vaccine for healthy adults?
    Patriarca PA; Strikas RA
    N Engl J Med; 1995 Oct; 333(14):933-4. PubMed ID: 7666882
    [No Abstract]   [Full Text] [Related]  

  • 12. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza--the forgotten vaccination.
    Martin DJ; Schoub BD
    S Afr Med J; 1997 Jul; 87(7):869-71. PubMed ID: 9259719
    [No Abstract]   [Full Text] [Related]  

  • 14. The economic implications of influenza vaccination for adults with asthma.
    Trogdon JG; Nurmagambetov TA; Thompson HF
    Am J Prev Med; 2010 Nov; 39(5):403-10. PubMed ID: 20965377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WHO guide on the economic evaluation of influenza vaccination.
    Newall AT; Chaiyakunapruk N; Lambach P; Hutubessy RCW
    Influenza Other Respir Viruses; 2018 Mar; 12(2):211-219. PubMed ID: 29024434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs.
    Ibuka Y; Paltiel AD; Galvani AP
    Med Decis Making; 2012; 32(3):442-6. PubMed ID: 22472916
    [No Abstract]   [Full Text] [Related]  

  • 17. Opening and continuing the discussion on influenza vaccination timing.
    Ryan KJ; Rousculp MD
    Am J Manag Care; 2010 Aug; 16(8):628-9; author reply 629-30. PubMed ID: 20737745
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic value of influenza vaccination.
    de Waure C; Veneziano MA; Cadeddu C; Capizzi S; Specchia ML; Capri S; Ricciardi W
    Hum Vaccin Immunother; 2012 Jan; 8(1):119-29. PubMed ID: 22251999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmaco-economics of anti-influenza vaccinations].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2003 Jun; 14(84):679-81. PubMed ID: 14524303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
    Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
    Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.